Early movers: Estée Lauder, Abiomed & more

A trader works on the floor of the New York Stock Exchange.
Adam Jeffery | CNBC
A trader works on the floor of the New York Stock Exchange.

Take a look at some of Tuesday's early movers:

Abiomed's miniature blood pump system that maintains heart function and circulation received approval from the U.S. Food and Drug Administration.

Estée Lauder—upgraded to "outperform" from "market perform" at Wells Fargo, citing accelerating growth in the United States and growth in emerging markets, as well as working capital improvement.

Kimberly-Clark—upgraded to "outperform" from "market perform" at Wells Fargo, noting a "favorable risk/reward compared to the broader staples group for what we see as an under-appreciated emerging markets growth engine."

Business research firm IHS cut its adjusted profit forecast and trimmed its revenue expectations, citing capital expenditure cuts by oil producers amid the decline in oil and the strong dollar. About 40 percent of IHS revenue comes from energy companies.

Ross Stores announced a two-for-one stock split, to be paid in the form of a 100 percent stock divided on June 11 to holders as of April 22.

General Motors is investing $350 million to build its next-generation Chevrolet Cruze compact in Mexico, which is part of a previously announced $5 billion investment plan in the region.

Billionaire Carl Icahn increased his stake in Chesapeake Energy to 73 million shares after the close on Monday, an increase from 66 million shares in December. The oil and gas company lowered its 2015 capital expenditures by $500 million on low commodity prices.

Xcel Energy – Barclays upgraded its rating to "overweight" on expectation of constructive outcome to Northern States Power-MN's multi-year electric rate case. The target price was decreased to $39 from $41.

Nice Systems—JMP downgraded the big data collection and analytics firm to "market perform" from "market outperform," citing valuation.